Global IVD Infectious Disease Market Size By Type (Biochemical Diagnosis, Immune Diagnosis), By Application (Personal, Commercial), By Region, And Segment Forecasts, 2023 to 2032

The Global IVD Infectious Disease Market was valued at USD 28.5 billion in 2023 and is projected to surpass USD 47.2 billion by 2031, growing at a CAGR of 6.5% during the forecast period from 2023 to 2031. The market's growth is primarily driven by the increasing prevalence of infectious diseases, advancements in in-vitro diagnostic (IVD) technologies, and the growing demand for rapid and accurate disease detection.

IVD infectious disease diagnostics play a crucial role in identifying pathogens responsible for infections such as HIV, tuberculosis, hepatitis, respiratory infections, and sexually transmitted diseases. The rising global burden of infectious diseases, increasing awareness about early diagnosis, and government initiatives to control outbreaks are further fueling market expansion.

Market Drivers

Rising Prevalence of Infectious Diseases

The increasing incidence of diseases like HIV/AIDS, tuberculosis, hepatitis, and COVID-19 is driving demand for IVD solutions. The rise in antimicrobial resistance and emerging infectious diseases also highlight the need for improved diagnostics.

Advancements in Diagnostic Technologies

Innovations such as molecular diagnostics, point-of-care (POC) testing, next-generation sequencing (NGS), and immunodiagnostics are enhancing accuracy, speed, and efficiency in infectious disease detection.

Growing Demand for Point-of-Care (POC) Testing

The shift toward rapid and portable testing solutions is boosting demand for POC diagnostic devices, especially in resource-limited settings.

Government and WHO Initiatives

Increased funding and initiatives by global health organizations, such as WHO, CDC, and UNAIDS, to control infectious disease outbreaks are creating significant growth opportunities.

Market Restraints

High Costs of Advanced Diagnostic Tools

The cost of molecular diagnostic tests, PCR-based assays, and NGS platforms can be a barrier to adoption, particularly in low- and middle-income countries.

Stringent Regulatory Requirements

The complex approval process for new IVD products and compliance with regulatory standards like FDA (U.S.), CE Mark (Europe), and China NMPA can slow down market entry.

Market Opportunities

Growing Adoption of AI and Machine Learning in IVD

The integration of AI-driven diagnostic algorithms and digital pathology in infectious disease testing is enhancing efficiency and accuracy.

Expanding Market in Emerging Economies

Countries like India, China, Brazil, and South Africa are witnessing rising demand for low-cost, high-efficiency diagnostic solutions, presenting vast opportunities for market players.

Increased Use of Self-Testing Kits

The demand for at-home self-test kits for diseases like HIV, COVID-19, and STDs is rapidly growing, providing manufacturers with a new revenue stream.

Market by System Type Insights

Molecular Diagnostics Segment Dominates

The molecular diagnostics segment held the largest market share in 2023 due to its high accuracy in pathogen detection. PCR-based and next-generation sequencing (NGS) platforms are particularly gaining traction.

Point-of-Care (POC) Testing is Growing Rapidly

With the need for faster, on-the-spot diagnostics, the POC testing segment is expected to grow at the highest CAGR during the forecast period.

Market by End-Use Insights

Hospitals & Diagnostic Laboratories Hold the Largest Share

Hospitals remain the largest end-users of IVD infectious disease solutions, accounting for over 50% of the market share in 2023.

Home Care and Clinics Witness Rising Demand

The home care segment is experiencing significant growth due to the availability of self-testing kits for HIV, COVID-19, and influenza.

Market by Regional Insights

North America Leads the Market

North America dominated the market in 2023 due to high healthcare expenditure, a well-established diagnostic infrastructure, and the presence of key players.

Asia-Pacific is the Fastest-Growing Region

Asia-Pacific is expected to witness the highest CAGR during the forecast period, driven by rising infectious disease prevalence, increasing investments in healthcare infrastructure, and growing demand for POC testing.

Competitive Scenario

Key players operating in the global IVD infectious disease market include:

Roche Diagnostics

Abbott Laboratories

Siemens Healthineers

bioMérieux

BD (Becton, Dickinson and Company)

Thermo Fisher Scientific

Danaher Corporation

Qiagen N.V.

Hologic, Inc.

Bio-Rad Laboratories, Inc.

These companies are focusing on strategic collaborations, product launches, and regulatory approvals to strengthen their market presence.

Scope of Work – Global IVD Infectious Disease Market

Report Metric Details

Market Size (2023) USD 28.5 billion

Projected Market Size (2031) USD 47.2 billion

CAGR (2023-2031) 6.5%

Key Segments By System Type (Molecular Diagnostics, Immunodiagnostics, POC Testing), By End-Use (Hospitals, Diagnostic Laboratories, Home Care)

Leading Region North America

Key Market Players Roche, Abbott, Siemens Healthineers, BD, bioMérieux, Thermo Fisher Scientific, Danaher Corporation, Qiagen, Hologic

Market Drivers Rising Infectious Disease Prevalence, Advancements in IVD Technologies, Government & WHO Initiatives

Market Opportunities AI & Digital Pathology, Self-Testing Kits, Expansion in Emerging Markets

Key Market Developments

January 2024: Roche Diagnostics launched a new AI-powered molecular diagnostic platform for infectious diseases.

November 2023: Abbott received FDA approval for its next-generation POC testing device for rapid detection of bacterial infections.

September 2023: Siemens Healthineers expanded its IVD testing portfolio with innovative multiplex PCR assays for simultaneous pathogen detection.

July 2023: Thermo Fisher Scientific partnered with WHO to provide affordable molecular diagnostic tests for emerging infectious diseases in Africa.

May 2023: bioMérieux introduced an advanced AI-powered immunodiagnostics platform for real-time infectious disease detection.

FAQs

What is the current market size of the Global IVD Infectious Disease Market?

The market was valued at USD 28.5 billion in 2023.

What is the major growth driver of the Global IVD Infectious Disease Market?

The primary growth driver is the rising prevalence of infectious diseases and advancements in diagnostic technologies.

Which is the largest region during the forecast period in the Global IVD Infectious Disease Market?

North America holds the largest market share due to high healthcare spending and an established diagnostic infrastructure.

Which segment accounted for the largest market share in the Global IVD Infectious Disease Market?

The Molecular Diagnostics segment dominated in 2023 due to its high accuracy in pathogen detection.

Who are the key market players in the Global IVD Infectious Disease Market?

Major players include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, bioMérieux, BD, Thermo Fisher Scientific, and Danaher Corporation.

This comprehensive report provides valuable insights into the market landscape, key growth drivers, industry challenges, and future opportunities, making it an essential resource for businesses and stakeholders in the IVD infectious disease diagnostics market.